How the CMO of Sage Therapeutics Positioned a New Indication for FDA Approval episode artwork

EPISODE · Dec 2, 2019 · 36 MIN

How the CMO of Sage Therapeutics Positioned a New Indication for FDA Approval

from PharmaTalkRadio · host Conference Forum

In this session recorded at the 7th annual Chief Medical Officer Summit, Dr Steve Kanes, Chief Medical Officer, Sage Therapeutics, discusses how a company considered as an "up and comer" in the Cambridge biotech sector navigated the development and approval of the first treatment specifically designed for postpartum depression. Learn more at theconferenceforum.org

In this session recorded at the 7th annual Chief Medical Officer Summit, Dr Steve Kanes, Chief Medical Officer, Sage Therapeutics, discusses how a company considered as an "up and comer" in the Cambridge biotech sector navigated the development and approval of the first treatment specifically designed for postpartum depression. Learn more at theconferenceforum.org

NOW PLAYING

How the CMO of Sage Therapeutics Positioned a New Indication for FDA Approval

0:00 36:39

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of PharmaTalkRadio?

This episode is 36 minutes long.

When was this PharmaTalkRadio episode published?

This episode was published on December 2, 2019.

What is this episode about?

In this session recorded at the 7th annual Chief Medical Officer Summit, Dr Steve Kanes, Chief Medical Officer, Sage Therapeutics, discusses how a company considered as an "up and comer" in the Cambridge biotech sector navigated the development and...

Can I download this PharmaTalkRadio episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!